SOLV Stock Analysis: Solventum | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 13.154m USD | 12M Return: 1.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 103M
Qual. Beats: 1
Rev. Trend: 84.5%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 2.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solventum Corporation (NYSE: SOLV) is a diversified healthcare company that develops, manufactures, and commercializes a broad portfolio of medical and healthcare solutions across three operating segments: Medsurg (wound care, sterilization assurance, surgical supplies, and medical electrodes), Dental Solutions (brackets, aligners, bonding agents, and restorative products), and Health Information Systems (clinical documentation, coding automation, speech recognition, and data analytics software). The company sells through multiple channels, including direct-to-consumer, distribution, key account management, inside sales, and e-commerce, and operates in both the U.S. and international markets. Solventum was incorporated in 2023, is headquartered in Eagan, Minnesota, and went public on March 26, 2024, with a current large-cap market capitalization of approximately $13 billion USD.
Solventum was spun off from 3Ms healthcare division in 2024, which is reflected in its diversified mix of legacy medical consumables, dental products, and health IT software. This hybrid business model-combining recurring medical device and consumables revenue with healthcare informatics software-is relatively uncommon among large-cap healthcare equipment peers, many of which focus more narrowly on either devices or health IT.
- Post-spin debt from 3M separation pressures margins and capital allocation
- Medsurg wound care and sterilization products anchor segment revenue
- Dental Solutions growth hinges on orthodontic pricing and market share
| Net Income: 1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -4.09 > 1.0 |
| NWC/Revenue: 2.87% < 20% (prev 5.86%; Δ -2.99% < -1%) |
| CFO/TA 0.01 > 3% & CFO 151.0m > Net Income 1.43b |
| Net Debt (4.73b) to EBITDA (2.75b): 1.72 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (175.5m) vs 12m ago 0.40% < -2% |
| Gross Margin: 53.67% > 18% (prev 54.59%; Δ -0.92% > 0.5%) |
| Asset Turnover: 57.73% > 50% (prev 57.19%; Δ 0.54% > 0%) |
| Interest Coverage Ratio: 6.54 > 6 (EBIT TTM 2.00b / Interest Expense TTM 305.0m) |
| A: 0.02 (Total Current Assets 3.58b - Total Current Liabilities 3.35b) / Total Assets 14.1b |
| B: 0.13 (Retained Earnings 1.81b / Total Assets 14.1b) |
| C: 0.14 (EBIT TTM 2.00b / Avg Total Assets 14.3b) |
| D: 0.54 (Book Value of Equity 4.97b / Total Liabilities 9.13b) |
| Altman-Z'' = 2.04 = BBB |
| DSRI: 0.96 (Receivables 1.06b/1.11b, Revenue 8.26b/8.31b) |
| GMI: 1.02 (GM 54.59% / 53.67%) |
| AQI: 0.90 (AQ_t 0.64 / AQ_t-1 0.71) |
| SGI: 0.99 (Revenue 8.26b / 8.31b) |
| TATA: 0.09 (NI 1.43b - CFO 151.0m) / TA 14.1b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 76.70 with a total of 399,181 shares traded. Over the past week, the price has changed by -2.01%, over one month by -5.24%, over three months by +16.58% and over the past year by +1.08%.
Current recommended Stop Loss: 70.40 (which is 8.2% or 2.7 ATR below the current price).
Solventum has received a consensus analysts rating of 3.25. Therefore, it is recommended to hold SOLV.
- StrongBuy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 82.1 | 7% |
P/E Trailing = 9.1961
P/E Forward = 11.4679
P/S = 1.5922
P/B = 2.6196
P/EG = 1.2198
Revenue TTM = 8.26b USD
EBIT TTM = 2.00b USD
EBITDA TTM = 2.75b USD
Long Term Debt = 4.58b USD (from longTermDebt, last quarter)
Short Term Debt = 505.0m USD (from shortTermDebt, last quarter)
Debt = 5.29b USD (from shortLongTermDebtTotal, last quarter) + Leases 207.0m
Net Debt = 4.73b USD (calculated: Debt 5.29b - CCE 561.0m)
Enterprise Value = 17.9b USD (13.2b + Debt 5.29b - CCE 561.0m)
Interest Coverage Ratio = 6.54 (Ebit TTM 2.00b / Interest Expense TTM 305.0m)
EV/FCF = -88.08x (Enterprise Value 17.9b / FCF TTM -203.0m)
FCF Yield = -1.14% (FCF TTM -203.0m / Enterprise Value 17.9b)
FCF Margin = -2.46% (FCF TTM -203.0m / Revenue TTM 8.26b)
Net Margin = 17.33% (Net Income TTM 1.43b / Revenue TTM 8.26b)
Gross Margin = 53.67% ((Revenue TTM 8.26b - Cost of Revenue TTM 3.83b) / Revenue TTM)
Gross Margin QoQ = 54.66% (prev 49.30%)
Tobins Q-Ratio = 1.27 (Enterprise Value 17.9b / Total Assets 14.1b)
Interest Expense / Debt = 5.77% (Interest Expense 305.0m / Debt 5.29b)
Taxrate = 15.32% (259.0m / 1.69b)
NOPAT = 1.69b (EBIT 2.00b * (1 - 15.32%))
Current Ratio = 1.07 (Total Current Assets 3.58b / Total Current Liabilities 3.35b)
Debt / Equity = 1.06 (Debt 5.29b / totalStockholderEquity, last quarter 4.97b)
Debt / EBITDA = 1.72 (Net Debt 4.73b / EBITDA 2.75b)
Debt / FCF = -23.28 (negative FCF - burning cash) (Net Debt 4.73b / FCF TTM -203.0m)
Total Stockholder Equity = 4.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.01% (Net Income 1.43b / Total Assets 14.1b)
RoE = 30.71% (Net Income TTM 1.43b / Total Stockholder Equity 4.66b)
RoCE = 21.61% (EBIT 2.00b / Capital Employed (Equity 4.66b + L.T.Debt 4.58b))
RoIC = 15.59% (NOPAT 1.69b / Invested Capital 10.8b)
WACC = 7.25% (E(13.2b)/V(18.4b) * Re(8.20%) + D(5.29b)/V(18.4b) * Rd(5.77%) * (1-Tc(0.15)))
Discount Rate = 8.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 0.71%
[DCF] Fair Price = unknown (Cash Flow -203.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.96 | # QB: 1
Revenue Correlation: 84.45 | Revenue CAGR: 1.13% | SUE: 2.06 | # QB: 4
EPS current Quarter (2026-06-30): EPS=1.90 | Chg30d=+0.62% | Revisions=-17% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.41 | Chg30d=-1.26% | Revisions=+0% | Analysts=13
EPS current Year (2026-12-31): EPS=6.55 | Chg30d=-0.09% | Revisions=-12% | GrowthEPS=+7.2% | GrowthRev=-1.5%
EPS next Year (2027-12-31): EPS=7.05 | Chg30d=+0.20% | Revisions=-29% | GrowthEPS=+7.8% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: -24% (up=5, down=9)